GenSight Biologics strengthens its management team to support the launch of LUMEVOQ® in Europe

GenSight Biologics Reports Interim Financial Results for the First Half of 2022

GenSight Biologics reports 5 years’ data showing sustained efficacy and safety following one-time treatment with LUMEVOQ®

GenSight Biologics Announces Participation and Presentation of GS010 Clinical Data at EUNOS 2022

GenSight Biologics Announces Publication of a Study of the impact of LHON disease on the lives of Patients and Relatives in Journal of Neuro-Ophthalmology

Annual General Meeting on May 25, 2022 Procedures for obtaining preparatory documents for the General Meeting

GenSight Biologics Announces the Filing of its 2021 Universal Registration Document

GenSight Biologics Reports Cash Position and Revenues as of March 31, 2022

GenSight Biologics Granted Six-Month Extension in LUMEVOQ® European Regulatory Review

GenSight Biologics Reports Full Year 2021 Consolidated Financial Results